Як відкрили вірус гепатиту С, або детективні пошуки вірусологів «мовчазного вбивці»
Нобелівська премія з фізіології та медицини 2020 року
DOI:
https://doi.org/10.15407/visn2020.12.003Ключові слова:
Nobel Prize in Physiology or Medicine, Harvey James Alter, Michael Houghton, Charles M. Rice, Hepatitis C virusАнотація
Нобелівську премію з фізіології та медицини у 2020 р. присуджено двом американським ученим — Гарві Джеймсу Альтеру (Harvey James Alter) з Національного інституту охорони здоров'я США та Чарльзу Райсу (Charles M. Rice) з Рокфеллерівського університету, а також британському досліднику Майклу Гоутену (Michael Houghton), який нині працює в Альбертському університеті в Канаді, за «відкриття вірусу гепатиту C». У пресрелізі Нобелівського комітету зазначено, що дослідження цьогорічних лауреатів, які й досі продовжують цю роботу, дали людству неоціненну користь, дозволивши розробити ефективні методи діагностики та заходи з профілактики і лікування цієї інфекції.
Посилання
Physiology or Medicine. Citation Laureates 2020. https://clarivate.com/webofsciencegroup/citation-laureates/physiology-or-medicine/
Press release: The Nobel Prize in Physiology or Medicine 2020. https://www.nobelprize.org/prizes/medicine/2020/press-release/
famous scientific awards. Dekatop.com. 23.02.2016. (in Russian). https://dekatop.com/archives/9911
Harvey J. Alter. Wikipedia. https://en.wikipedia.org/wiki/Harvey_J._Alter
Michael Houghton (virologist). Wikipedia. https://en.wikipedia.org/wiki/Michael_Houghton_(virologist)
Charles M. Rice. Wikipedia. https://en.wikipedia.org/wiki/Charles_M._Rice
Hepatitis. World Health Organization. https://www.who.int/health-topics/hepatitis#tab=tab_1
MacCallum F.O. Homologous serum hepatitis. Lancet. 1947. 250(6480): 691–692. DOI: https://doi.org/10.1016/S0140-6736(47)90722-8
Hepatitis A. https://en.wikipedia.org/wiki/Hepatitis_A
Hepatitis A. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-a
Hepatitis E. https://en.wikipedia.org/wiki/Hepatitis_E
Hepatitis E. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-e
Hepatitis B. https://en.wikipedia.org/wiki/Hepatitis_B
Hepatitis B. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
Hepatitis D. https://en.wikipedia.org/wiki/Hepatitis_D
Hepatitis D. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d
Hepatitis C. https://en.wikipedia.org/wiki/Hepatitis_C
Hepatitis C. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Elgharably A., Gomaa A.I., Crossey M.M.E., Norsworthy P.J., Waked I., Taylor-Robinson S.D. Hepatitis C in Egypt — past, present, and future. Int. J. Gen. Med. 2017. 10: 1–6. DOI: https://doi.org/10.2147/IJGM.S119301
Masucci M.G., Hedestam G.K. The discovery of Hepatitis C virus. https://www.nobelprize.org/prizes/medicine/2020/advanced-information/
Blumberg B.S. Polymorphisms of the serum proteins and the development of iso-preciptins in transfused patients. Bull. N. Y. Acad. Med. 1964. 40(5): 377–386. DOI: https://doi.org/10.1142/9789812813688_0017
Bayer M.E., Blumberg B.S., Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis. Nature. 1968. 218(5146):1057–1059. DOI: https://doi.org/10.1038/2181057a0
Barry Blumberg. Obituary. The Economist. April 28, 2011. https://www.economist.com/obituary/2011/04/28/barry-blumberg
World Hepatitis Day. Wikipedia. https://en.wikipedia.org/wiki/World_Hepatitis_Day
Alter H.J. The road not taken or how I learned to love the liver: A personal perspective on hepatitis history. Hepatology. 2014. 59(1): 4–12. DOI: https://doi.org/10.1002/hep.26787
Feinstone S.M., Kapikian A.Z., Purcell R.H. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. Science. 1973. 182(4116): 1026–1028. DOI: https://doi.org/10.1126/science.182.4116.1026
Blumberg B.S., Alter H.J., Visnich S. A "New" Antigen in Leukemia Sera. JAMA. 1965. 191(7): 541–546. DOI: https://doi.org/10.1001/jama.1965.03080070025007
Feinstone S.M., Kapikian A.Z., Purcell R.H., Alter H.J., Holland P.V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N. Engl. J. Med. 1975. 292(15): 767–770. DOI: https://doi.org/10.1056/nejm197504102921502
Alter H.J., Holland P.V., Purcell R.H., Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet. 1978. 311(8062): 459–463. DOI: https://doi.org/10.1016/s0140-6736(78)90131-9
Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989. 244(4902): 359–362. DOI: https://doi.org/10.1126/science.2523562
Kuo G., Choo Q.L., Alter H.J., Gitnick G.L., Redeker A.G., Purcell R.H., Miyamura T., Dienstag J.L., Alter M.J., Stevens C.E. al et. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989. 244(4902): 362–364. DOI: https://doi.org/10.1126/science.2496467
Wang K.S., Choo Q.L., Weiner A.J., Ou J.H., Najarian R.C., Thayer R.M., Mullenbach G.T., Denniston K.J., Gerin J.L., Houghton M. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature. 1986. 323(6088): 508–514. DOI: https://doi.org/10.1038/323508a0
Tanaka T., Kato N., Cho M.J., Shimotohno K. A novel sequence found at the 3' terminus of hepatitis C virus genome. Biochem Biophys. Res. Commun. 1995. 215(2): 744–749. DOI: https://doi.org/10.1006/bbrc.1995.2526
Kolykhalov A.A., Feinstone S.M., Rice C.M. Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. J. Virol. 1996. 70(6): 3363–3371. DOI: https://doi.org/10.1128/jvi.70.6.3363-3371.1996
Kolykhalov A.A., Agapov E.V., Blight K.J., Mihalik K., Feinstone S.M., Rice C.M. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 1997. 277(5325): 570–574. DOI: https://doi.org/10.1126/science.277.5325.570
Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999. 285(5424): 110–113. DOI: https://doi.org/10.1126/science.285.5424.110
Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R.T., Tyrrell D.L.J., Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001. 7(8): 927–933. DOI: https://doi.org/10.1038/90968
Zhao X., Tang Z.Y., Klumpp B., Wolff-Vorbeck G., Barth H., Levy S., von Weizsäcker F., Blum H.E., Baumert T.F. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J. Clin. Invest. 2002. 109(2): 221–232. DOI: https://doi.org/10.1172/JCI13011
Sanada T., Tsukiyama-Kohara K., Shin-I T., Yamamoto N., Kayesh M.E.H., Yamane D., Takano J.I., Shiogama Y., Yasutomi Y., Ikeo K., Gojobori T., Mizokami M., Kohara M. Construction of complete Tupaia belangeri transcriptome database by whole-genome and comprehensive RNA sequencing. Sci. Rep. 2019. 9(1): 12372. DOI: https://doi.org/10.1038/s41598-019-48867-x
Hepatitis C virus. Wikipedia. https://en.wikipedia.org/wiki/Hepatitis_C_virus
Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther. Adv. Chronic. Dis. 2011. 2(1): 39–45. DOI: https://doi.org/10.1177/2040622310384308
Arase Y., Suzuki F., Suzuki Y., Akuta N., Kawamura Y., Kobayashi M., Hosaka T., Sezaki H., Yatsuji H., Kobayashi M., Ikeda K., Kumada H. Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern. Med. 2007. 46(22): 1827–1832. DOI: https://doi.org/10.2169/internalmedicine.46.0289
Lin C., Rice C.M. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. Proc. Natl. Acad. Sci. USA. 1995. 92(17): 7622-7626. DOI: https://doi.org/10.1073/pnas.92.17.7622
Bhatia H.K., Singh H., Grewal N., Natt N.K. Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J. Pharmacol. Pharmacother. 2014. 5(4): 278–284. DOI: https://doi.org/10.4103/0976-500X.142464.
Link J.O., Taylor J.G., Xu L., Mitchell M., Guo H., Liu H., Kato D., Kirschberg T., Sun J., Squires N., Parrish J., Kellar T., Yang Z.Y., Yang C., Matles M., Wang Y., Wang K., Cheng G., Tian Y., Mogalian E., Mondou E., Cornpropst M., Perry J., Desai M.C. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 2014. 57(5): 2033–2046. DOI: https://doi.org/10.1021/jm401499g
Gane E.J., Stedman C.A., Hyland R.H., Ding X., Svarovskaia E., Subramanian G.M., Symonds W.T., McHutchison J.G., Pang P.S. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014. 146(3): 736–743.e1. DOI: https://doi.org/10.1053/j.gastro.2013.11.007
Pol S., Bourliere M., Lucier S., Hezode C., Dorival C., Larrey D., Bronowicki J.P., Ledinghen V.D., Zoulim F., Tran A., Metivier S., Zarski J.P., Samuel D., Guyader D., Marcellin P., Minello A., Alric L., Thabut D., Chazouilleres O., Riachi G., Bourcier V., Mathurin P., Loustaud-Ratti V., D'Alteroche L., Fouchard-Hubert I., Habersetzer F., Causse X., Geist C., Rosa I., Gournay J., Saillard E., Billaud E., Petrov-Sanchez V., Diallo A., Fontaine H., Carrat F.; ANRS/AFEF HEPATHER study group. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J. Hepatol. 2017. 66(1): 39–47. DOI: https://doi.org/10.1016/j.jhep.2016.08.021
Weisberg I.S., Jacobson I.M. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection. Expert. Opin. Pharmacother. 2017. 18(5): 535–543. DOI: https://doi.org/10.1080/14656566.2017.1282459
Petrenko A., Gopka A. Sovaldi: the history of the best-selling drug in the entire history of the pharmaceutical industry. Forbes.ru. 02.03.2017. (in Russian). https://www.forbes.ru/tehnologii/338761-sovaldi-istoriya-samogo-prodavaemogo-preparata-za-vsyu-istoriyu-farmotrasli
Indian generics for hepatitis C. (in Russian). https://sofosbuvir.su/indiyskie-generiki
Lindow M., Kauppinen S. Discovering the first microRNA-targeted drug. J. Cell Biol. 2012. 199(3): 407–412. DOI: https://doi.org/10.1083/jcb.201208082
Bonneau E., Neveu B., Kostantin E., Tsongalis G.J., De Guire V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC. 2019. 30(2): 114–127. eCollection.
van der Ree M.H., de Vree J.M., Stelma F., Willemse S., van der Valk M., Rietdijk S., Molenkamp R., Schinkel J., van Nuenen A.C., Beuers U., Hadi S., Harbers M., van der Veer E., Liu K., Grundy J., Patick A.K., Pavlicek A., Blem J., Huang M., Grint P., Neben S., Gibson N.W., Kootstra N.A., Reesink H.W. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017. 389(10070): 709–717. DOI: https://doi.org/10.1016/S0140-6736(16)31715-9
Echeverria N., Moratorio G., Cristina J., Moreno P. Hepatitis C virus genetic variability and evolution. World J. Hepatol. 2015. 7(6): 831–845. DOI: https://doi.org/10.4254/wjh.v7.i6.831.
Lingala S., Ghany M.G. Natural history of hepatitis C. Gastroenterol. Clin. North. Am. 2015. 44(4): 717–734. DOI: https://doi.org/10.1016/j.gtc.2015.07.003
Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium K., Kuo C., Kansopon J., McFarland J., Tabrizi A., Ching K., Moss B., Cummins L.B., Houghton M., Muchmore E. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. USA. 1994. 91(4): 1294–1298. DOI: https://doi.org/10.1073/pnas.91.4.1294
Frey S.E., Houghton M., Coates S., Abrignani S., Chien D., Rosa D., Pileri P., Ray R., Di Bisceglie A.M., Rinella P., Hill H., Wolff M.C., Schultze V., Han J.H., Scharschmidt B., Belshe R.B. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010. 28(38): 6367–73. DOI: https://doi.org/10.1016/j.vaccine.2010.06.084
Chen F., Nagy K., Chavez D., Willis S., McBride R., Giang E., Honda A., Bukh J., Ordoukhanian P., Zhu J., Frey S., Lanford R., Law M. Antibody responses to immunization with HCV envelope glycoproteins as a baseline for B-cell-based vaccine development. Gastroenterology. 2020. 158(4): 1058–1071.e6. DOI: https://doi.org/10.1053/j.gastro.2019.11.282
Castelli M., Clementi N., Pfaff J., Sautto G.A., Diotti R.A., Burioni R., Doranz B.J., Dal Peraro M., Clementi M., Mancini N. A biologically-validated HCV E1E2 heterodimer structural model. Sci. Rep. 2017. 7(1): 214. DOI: https://doi.org/10.1038/s41598-017-00320-7
Christiansen D., Earnest-Silveira L., Chua B., Meuleman P., Boo I., Grubor-Bauk B., Jackson D.C., Keck Z.Y., Foung S.K.H., Drummer H.E., Gowans E.J., Torresi J. Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. Sci. Rep. 2018. 8(1): 6483. DOI: https://doi.org/10.1038/s41598-018-24762-9
Wang X., Yan Y., Gan T., Yang X., Li D., Zhou D., Sun Q., Huang Z., Zhong J. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut. 2019. 68(1): 140–149. DOI: https://doi.org/10.1136/gutjnl-2017-314870
Swadling L., Capone S., Antrobus R.D., Brown A., Richardson R., Newell E.W., Halliday J., Kelly C., Bowen D., Fergusson J., Kurioka A., Ammendola V., Del Sorbo M., Grazioli F., Esposito M.L., Siani L., Traboni C., Hill A., Colloca S., Davis M., Nicosia A., Cortese R., Folgori A., Klenerman P., Barnes E. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 2014. 6(261): 261ra153. DOI: https://doi.org/10.1126/scitranslmed.3009185
From NIH: Trial Evaluating Experimental Hepatitis C Vaccine Concludes https://www.hhs.gov/hepatitis/blog/2019/06/05/experimental-hepatitis-c-vaccine-trial-concludes.html
Global hepatitis report, 2017. https://www.who.int/publications/i/item/global-hepatitis-report-2017
Ukrainians are encouraged to take a free test for viral hepatitis (in Ukrainian). https://moz.gov.ua/article/news/ukrainciv-zaklikajut-projti-bezoplatnij-test-na-virusni-gepatiti
Global health sector strategy on viral hepatitis 2016-2021. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
Scott N., Kuschel C., Pedrana A., Schroeder S., Howell J., Thompson A., Wilson D.P., Hellard M. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol Hepatol. 2020. 5(10): 940-947. DOI: https://doi.org/10.1016/S2468-1253(20)30008-X
Alothaid H., Aldughaim M.S.K., El Bakkouri K., AlMashhadi S., Al-Qahtani A.A. Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID19 progression: a review of potential targets for diagnosis and treatment. Channels (Austin). 2020. 14(1): 403-412. DOI: https://doi.org/10.1080/19336950.2020.1837439
